The Food and Drug Administration has approved the study of antipsychotic drug Abilify (aripiprazole) for the treatment of manic and mixed episodes due to bipolar I disorder in children ages 10 to 17....
The Food and Drug Administration has approved the study of antipsychotic drug Abilify (aripiprazole) for the treatment of manic and mixed episodes due to bipolar I disorder in children ages 10 to 17. Abilify is already used to treat bipolar disease in adults.
Abilify was discovered by Japan-based Otsuka Pharmaceutical Co., which has an agreement with Bristol-Myers Squibb Co. to co-promote the drug in the US until 2012. The Supplemental New Drug Application reflects an increased off-label use of the drug in older children for behavioral issues.
Continuous glucose monitors ease care for parents of young children with T1D
December 5th 2023Continuous glucose monitors have been found to improve sleep for parents of young children with type 1 diabetes and may help alleviate the care burden associated with the condition, according to a study conducted in France.
AAP cautions against low-carbohydrate diets for children at risk for diabetes
December 1st 2023According to the American Academy of Pediatrics (AAP), it is recommended that 45% to 65% of total daily calories come from carbohydrates, though very low-carbohydrate diets allow for 20 to 50 grams per day.